Supranuclear Palsy, Progressive
9
2
2
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
22.2%
2 terminated out of 9 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.
More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease
Application of Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms
Study of BIIB092 in Participants With Progressive Supranuclear Palsy
Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy